Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
NEW YORK, Dec. 15, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it has filed an appeal regarding a preliminary decision of the European Patent Office (EPO) to revoke the company's ANTISENILIN® patents. The preliminary decision of the EPO resulted from a challenge by major pharmaceutical companies that are co-developing Bapineuzumab, which is in Phase 3 clinical trials for Alzheimer's disease. Intellect has ANTISENILIN® patents pending in the United States and has been granted patents in Japan, China and several other countries. None of the patents granted outside Europe were challenged.
"We are quite disappointed by actions taken by Elan Pharmaceuticals and Wyeth as well as by the preliminary decision of the EPO during Oral Proceedings in The Hague in July. We are appealing that decision and remain confident regarding our ability to prevail at the level of the Appeals Board in Munich, Germany," said Daniel Chain, chairman and CEO of Intellect Neurosciences. "Importantly, Intellect's patents remain in force in key European countries pending the outcome of the appeal process. Moreover, Intellect has filed divisional patent applications, which we believe will result in robust new patents in Europe that should be resistant to challenge and will cover products currently in clinical development. The company has excellent representation in the US and Europe where it works with premier patent firms. We remain committed to maintaining and enforcing patent protection for our inventions and product candidates."
About Intellect Neurosciences, Inc.